False
August 17, 2026
3 min read
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
August 10, 2026
3 min read
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
July 14, 2026
3 min read
VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies
July 13, 2026
2 min read
Selected companies will receive earlier FDA engagement to support new US drug manufacturing facilities across small molecules, biologics, sterile injectables, and advanced therapies
False